There are steps we can take to improve access to lifesaving drugs for patients, including the ones listed in this Health Affairs post. #pharmacoequity
Essential Drugs Must Be Affordable And Accessible www.healthaffairs.org/content/fore... by @jbudhu.bsky.social @eddiecliff.bsky.social
Glad to have contributed to this study examining #Pharmacoequity of newer disease modifying therapies for patients with rheumatoid arthritis.
Take a look at our paper below!
📝: www.jrheum.org/content/52/1...
Pharmacoequity turned 4 years old last month!
Had a wonderful time in Ann Arbor last week as this year’s McKesson Equity Series Speaker @ the University of Michigan College of Pharmacy sharing on the past, present, and future of this growing field.
Let’s work together to achieve #Pharmacoequity! 💊
Every Wednesday evening for years I’ve opened the @nejm.org weekly email to dozens of the latest clinical trials of exciting new therapies.
Yet, the future diffusion and equitable dissemination & implementation of these drugs is FAR less studied.
So many opportunities to advance #Pharmacoequity. 💊
Love the idea of a series focused on tobacco cessation globally, esp the role of #Pharmacoequity. 💊
But not sure there is evidence to support that it’s “lagging knowledge” driving ⬇️ rates of treatment in low and middle income countries. 🤔
Hoping for more data ahead.
www.nejm.org/doi/full/10....
My patient recently lost his Medicaid insurance and couldn’t afford his meds.
Just calculated the cost of his 13 💊 which would be $2300/month. That’s around $27,500/year.
The FPL for a family of 4 is ~$32,000.
This is not sustainable for the health and lives of our patients!
#Pharmacoequity
Walked into a #RiteAid in CA yday that was EMPTY. Sad.
“The hundreds of stores that are set to close within the year will limit many Americans' access to 💊 resulting in "pharmacy deserts"—less-connected communities being left w/o nearby drugstores.
#Pharmacoequity
www.newsweek.com/rite-aid-cvs...
What an outstanding @cudeptofmedicine.bsky.social grand rounds presentation by the inspiring @uressien.bsky.social ! #pharmacoequity "Pursuing Pharmacoequity: The Case of Atrial Fibrillation"
‼️ New Simultaneous 📝 at #SGIM25.
In 2023, lecanemab became the 1st disease-modifying 💊 for Alzheimer’s disease.
Led by 🌟 Frank Zhou, we found that early uptake of lecanemab still appears to be marked by racial, ethnic & socioeconomic disparities.
jamanetwork.com/journals/jam...
#Pharmacoequity
In the meantime, if you’d like to give it a read, here’s the link to the article!
jamanetwork.com/journals/jam...
#Pharmacoequity
‼️ NEW Paper.
Led by @sudkrishnamurthy.bsky.social we found wide disparities in receipt of ERBB2-targeted 💊 for Medicare enrollees w. breast cancer, disparities that did narrow by 2019.
We need more research to identify strategies to improve cancer #Pharmacoequity.
jamanetwork.com/journals/jam...
Explore our latest breaking human rights news and publications on global migrant exploitation, the unethical use of human subjects in research, the breakdown of #democracy in #Bangladesh, and #pharmacoequity. www.humanrightsresearch.org/post/april-2...
#HumanRights #News #Research
Coined by Dr. Utibe Essien in 2021, pharmacoequity is the idea that everyone—regardless of race, income, or background—deserves access to appropriate medications for their health conditions. www.humanrightsresearch.org/post/pharmac... #humanrights #pharmacoequity #healthcare #discrimination #racism
“…11% of people said they could not afford medication and care within the past 3 months, the highest level in the four years the survey has been conducted.
Over 1/3 said if they were to need medical care, they would not be able to pay for it.”
#Pharmacoequity
www.nytimes.com/2025/04/02/h...
Support @PittCP3 this #PittDayofGiving! Your gift helps improve medication safety, affordability, & access for all, in addition to helping us prepare students & trainees for the next step in their #pharmacoequity careers. 💊
Donate today: giveto.pitt.edu/CP3
Such a treat to have my friend and LEADER, Dr. Jasmine Marcelin, as our Department of Medicine Grand Rounds speaker. 👩🏾⚕️
Her talk, “Antimicrobial Prescribing Disparities and the Pursuit of #Pharmacoequity” was data-filled and inspiring. ✨
NEW: The next 15 drugs chosen for Medicare price negotiation have been announced by the administration. 💊
Perhaps unsurprisingly but importantly, the list includes Ozempic and Wegovy.
#Pharmacoequity
apple.news/Ah_4w14VjRgS...
#Pharmacoequity is key to reducing health disparities. To help achieve this goal, Drs. Pranav Patel, Laura Happe, & CP3 alum @UREssien developed a framework to measure RxEquity domains.
Read more @amcporg #JMCP
www.jmcp.org/doi/10.18553...
CP3's RxEquity work: www.cp3.pitt.edu/research/pha...
CP3 hosted 2 conferences in 2024! We welcomed attendees in person & virtually to our 3rd #Pharmacoequity Conference, & Pitt Pharmacy had a successful inaugural OTC Hearing Aid & Hearing Self-Care Symposium.
5/7
CP3 folks had 3 grants funded in 2024! (& more are in review!)
Sarah Belcher: reporter.nih.gov/search/s-jof...
Coleman Drake: reporter.nih.gov/search/fyBS7...
& a grant from AHRQ for our #Pharmacoequity Conference!
4/7
Nice overview in the American Journal of Health-System Pharmacy on how pharmacists can incorporate #Pharmacoequity into the formulary review process…
…This will help ensure that the needs of vulnerable patient populations are being considered & addressed.
academic.oup.com/ajhp/advance...
Thanks to Mt. Sinai Department of Medicine and Med-Peds for the invitation to the Dr. Arnold Drapkin Memorial Lectureship today. ✨
Enjoyed being back home in NY.🗽
#Pharmacoequity
New study describing antibiotic prescribing variation for children in the hospital. #Pharmacoequity 💊
As I become more immersed in cancer care, I’m passionate about breaking down barriers. Every patient deserves access to life-saving treatments, regardless of income or location. Together, we can transform global health equity. 🌍💊 #Pharmacoequity jamanetwork.com/journals/jam...
New Position Statement from the American Academy of Allergy, Asthma, & Immunology highlighting the importance of #Pharmacoequity in the field of food allergy. 💊
Really exciting to see this concept expanding!
secure.jbs.elsevierhealth.com/action/getSh...
New app. Same vibes. ✈️
Excited for #AHA24! Looking forward to sharing our latest #AFib work and presenting on #Pharmacoequity with an all-⭐️ team @ the ABC Symposium.
But mostly ready to reconnect with friends & colleagues in the Chi. 💨
See y’all soon. 👊🏾
Sept. 29 is #WorldHeartDay. This year, let's work together to improve cardiovascular health for everyone.
#pharmacoequity
Recent work from CP3 folks:
link.springer.com/article/10.1...
www.acpjournals.org/doi/10.7326/...
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Registration for our #Pharmacoequity Conference is open! Excited to welcome keynote @fumikochino & other expert panelists.
🗺️@PittTweet or Zoom
🗓️May 3
Info/Register: calendar.pitt.edu/event/3rd_an...
Funding from @AHRQNews & sponsored by @Arnold_Ventures & @pittpharmacy
CP3's Dr. Coleman Drake led the 1st study examining local access to #buprenorphine. The team found that bup is much ⬇️accessible in areas w/racially & ethnically diverse populations.
Read more the Journal of Addiction Medicine
journals.lww.com/journaladdic...
#pharmacoequity
Loving pallonc and supponc peeps at #ASCOQLTY23. First sessions have been jam packed with high quality talks regarding cost of cancer care from emphasis on treatment over supportive drugs, the concept of #pharmacoequity and amazing #patientadvocate voices from physician patients MedSky OncSky hapc
